- Home
- ANTA vs PEPG Comparison
ANTA vs PEPG Comparison
Compare ANTA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | PEPG |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 317.6M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANTA | PEPG |
|---|---|---|
| Price | $10.17 | $5.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.50 | $9.50 |
| AVG Volume (30 Days) | 5.3K | ★ 855.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 669.18 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $65,033,103.00 | N/A |
| Revenue This Year | $69.27 | N/A |
| Revenue Next Year | $64.32 | N/A |
| P/E Ratio | $21.80 | ★ N/A |
| Revenue Growth | ★ 63.28 | N/A |
| 52 Week Low | $8.50 | $0.88 |
| 52 Week High | $27.72 | $6.72 |
Technical Indicators
Market Signals| Indicator | ANTA | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.83 |
| Support Level | N/A | $5.03 |
| Resistance Level | N/A | $6.72 |
| Average True Range (ATR) | 0.00 | 0.56 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 48.52 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.